Introdução
O que você precisa saber de cara
Artrite idiopática juvenil (AIJ), anteriormente conhecida como artrite reumatoide juvenil (ARJ), é a doença reumática crônica mais comum da infância, afetando aproximadamente de 3,8 a 400 em cada 100.000 crianças. Juvenil refere-se ao início da doença antes dos 16 anos de idade, enquanto idiopática refere-se a uma condição sem causa definida, e artrite é a inflamação dentro da articulação.
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Entender a doença
Do básico ao detalhe, leia no seu ritmo
Preparando trilha educativa...
Sinais e sintomas
O que aparece no corpo e com que frequência cada sintoma acontece
Partes do corpo afetadas
+ 21 sintomas em outras categorias
Características mais comuns
Os sintomas variam de pessoa para pessoa. Abaixo estão as 45 características clínicas mais associadas, ordenadas por frequência.
Linha do tempo da pesquisa
Encontrou um erro ou informação desatualizada? Sugira uma correção →
Genética e causas
O que está alterado no DNA e como passa nas famílias
Genes associados
7 genes identificados com associação a esta condição.
Transcriptional regulator mainly expressed in hematopoietic cells that plays a critical role in cellular growth, differentiation and immune response (PubMed:10961885, PubMed:37256972, PubMed:8943379). Plays a key role in the differentiation of T-helper 1 cells and the production of interferon-gamma (PubMed:12213961, PubMed:35614130). Also participates in multiple neutrophil functions including chemotaxis and production of the neutrophil extracellular traps (By similarity). After IL12 binding to
CytoplasmNucleus
Systemic lupus erythematosus 11
A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
Receptor for interleukin-2. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2. Probably in association with IL15RA, involved in the stimulation of neutrophil phagocytosis by IL15 (PubMed:15123770, PubMed:31040185)
Cell membrane
Immunodeficiency 63 with lymphoproliferation and autoimmunity
An autosomal recessive disorder characterized by immune dysregulation resulting in lymphoid proliferation, dermatitis, enteropathy, autoantibodies, hypergammaglobulinemia, and immunodeficiency with recurrent infections. Patients show increased susceptibility to viral infections, particularly cytomegalovirus disease.
Part of the TCR-CD3 complex present on T-lymphocyte cell surface that plays an essential role in adaptive immune response. When antigen presenting cells (APCs) activate T-cell receptor (TCR), TCR-mediated signals are transmitted across the cell membrane by the CD3 chains CD3D, CD3E, CD3G and CD247/CD3Z. All CD3 chains contain immunoreceptor tyrosine-based activation motifs (ITAMs) in their cytoplasmic domain. Upon TCR engagement, these motifs become phosphorylated by Src family protein tyrosine
Cell membrane
Immunodeficiency 25
An immunological deficiency characterized by T-cells impaired immune response to alloantigens, tetanus toxoid and mitogens.
Non-receptor type tyrosine-specific phosphatase that dephosphorylates receptor protein tyrosine kinases including INSR, EGFR, CSF1R, PDGFR. Also dephosphorylates non-receptor protein tyrosine kinases like JAK1, JAK2, JAK3, Src family kinases, STAT1, STAT3 and STAT6 either in the nucleus or the cytoplasm. Negatively regulates numerous signaling pathways and biological processes like hematopoiesis, inflammatory response, cell proliferation and differentiation, and glucose homeostasis. Plays a mult
Endoplasmic reticulumEndoplasmic reticulum-Golgi intermediate compartmentNucleusCytoplasmCell membrane
Receptor for interleukin-2. The receptor is involved in the regulation of immune tolerance by controlling regulatory T cells (TREGs) activity. TREGs suppress the activation and expansion of autoreactive T-cells
Membrane
Type 1 diabetes mellitus 10
A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical features are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.
Acts as a negative regulator of T-cell receptor (TCR) signaling by direct dephosphorylation of the Src family kinases LCK and FYN, ITAMs of the TCRz/CD3 complex, as well as ZAP70, VAV, VCP and other key signaling molecules (PubMed:16461343, PubMed:18056643). Associates with and probably dephosphorylates CBL. Dephosphorylates LCK at its activating 'Tyr-394' residue (PubMed:21719704). Dephosphorylates ZAP70 at its activating 'Tyr-493' residue (PubMed:16461343). Dephosphorylates the immune system a
Cytoplasm
Systemic lupus erythematosus
A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
Medicamentos aprovados (FDA)
2 medicamentos encontrados nos registros da FDA americana.
Variantes genéticas (ClinVar)
111 variantes patogênicas registradas no ClinVar.
Vias biológicas (Reactome)
28 vias biológicas associadas aos genes desta condição.
Diagnóstico
Os sinais que médicos procuram e os exames que confirmam
Tratamento e manejo
Remédios, cuidados de apoio e o que precisa acompanhar
Onde tratar no SUS
Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)
🇧🇷 Atendimento SUS — Poliartrite juvenil
Selecione um estado ou use sua localização para ver resultados.
Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.
Pesquisa ativa
Ensaios clínicos abertos e novidades científicas recentes
Ensaios em destaque
🟢 Recrutando agora
2 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.
Outros ensaios clínicos
19 ensaios clínicos encontrados, 2 ativos.
Publicações mais relevantes
Camptodactyly-Arthropathy-Coxa Vara-Pericarditis Syndrome without Camptodactyly: A Pediatric Case and Review of the Literature.
Camptodactyly-arthropathy-coxa vara-pericarditis syndrome is a rare autosomal recessive disorder with camptodactyly, non-inflammatory arthropathy, coxa vara, and pericarditis. Symptoms usually begin in early childhood with swelling of interphalangeal joints, wrists, and knees. Pericarditis is rare. It is caused by proteoglycan 4 gene mutations and often misdiagnosed as juvenile idiopathic arthritis due to overlapping features. A 4-year-old boy presented with 6 months of knee and wrist swelling and nocturnal pain. His parents were first-degree cousins, and a maternal uncle had rheumatoid arthritis. He had prior hip surgeries at 2.5 years. Examination showed swelling in knees, ankles, and wrists, and 30° wrist extension limitation. No systemic symptoms were noted. The erythrocyte sedimentation rate, C-reactive protein level, and antinuclear antibody test results were normal. Magnetic resonance imaging showed effusion and synovial thickening. Initially diagnosed with polyarticular juvenile idiopathic arthritis, he received methotrexate and etanercept. Due to progressive gait issues and radiographic coxa vara, diagnosis was revised. Genetic testing confirmed homozygous proteoglycan 4 (c.915delC) mutation. This case underscores an atypical camptodactyly-arthropathy-coxa vara-pericarditis presentation without camptodactyly. Persistent non-inflammatory arthropathy despite immunosuppression should raise suspicion for camptodactyly-arthropathy-coxa vara-pericarditis. Das Camptodaktylie-Arthropathie-Coxa-vara-Perikarditis (CACP)-Syndrom ist eine seltene autosomal-rezessive Erkrankung, die durch Camptodaktylie, nicht-entzündliche Arthropathie, Coxa vara und Perikarditis gekennzeichnet ist. Die Symptome beginnen typischerweise im frühen Kindesalter mit Schwellungen der Interphalangealgelenke, Handgelenke und Knie. Eine Perikarditis ist selten. Das Syndrom wird durch Mutationen im PRG4-Gen verursacht und aufgrund überlappender klinischer Merkmale häufig mit juveniler idiopathischer Arthritis (JIA) verwechselt. Ein 4-jähriger Junge stellte sich mit einer sechsmonatigen Vorgeschichte von Schwellungen und nächtlichen Schmerzen in den Knien und Handgelenken vor. Die Eltern waren Cousin und Cousine ersten Grades, ein mütterlicher Onkel hatte rheumatoide Arthritis. Im Alter von 2,5 Jahren hatte der Patient Operationen wegen Hüftdysplasie. Die körperliche Untersuchung ergab Schwellungen in Knien, Sprunggelenken und Handgelenken sowie eine 30°-Streckungseinschränkung in beiden Handgelenken. Systemische Symptome lagen nicht vor. ESR, CRP und ANA waren unauffällig. Die MRT zeigte Gelenkergüsse und synoviale Verdickungen. Zunächst wurde eine polyartikuläre JIA diagnostiziert und mit Methotrexat und später Etanercept behandelt. Aufgrund zunehmender Gangstörungen und radiologischer Zeichen einer Coxa vara wurde die Diagnose überdacht. Eine genetische Analyse bestätigte eine homozygote PRG4-Mutation (c.915delC). Dieser Fall verdeutlicht eine atypische Präsentation des CACP-Syndroms ohne Camptodaktylie. Eine persistierende, nicht-entzündliche Arthropathie trotz immunsuppressiver Therapie sollte den Verdacht auf ein CACP-Syndrom lenken.
Biologic treatment patterns and challenges in defining difficult-to-treat disease in children with polyarticular juvenile idiopathic arthritis: a real-world study.
To evaluate the clinical characteristics, and treatment patterns of difficult-to-treat (D2T) disease in children with polyarticular juvenile idiopathic arthritis (pJIA) treated with biologic disease-modifying antirheumatic drugs (bDMARDs). This single-center, cross-sectional study included children with RF-positive or RF-negative pJIA who received bDMARD. D2T defined according to EULAR criteria, as inadequate response to at least two bDMARDs with different mechanisms of action. Disease activity was assessed using the JADAS-27. Treatment patterns, switches, and factors associated with D2T were analyzed. A total of 59 pJIA patients (79.9% female) were included, with a median follow-up of 60 months. Ten patients (16.9%) fulfilled the criteria for D2T disease after a follow-up duration of 36 months. At diagnosis, D2T patients had significantly higher inflammatory markers than non-D2T patients, with higher median CRP (45 vs. 12 mg/L, p = 0.002) and ESR (77 vs. 38 mm/h, p = 0.003) values. In univariate analyses, higher CRP, ESR, temporomandibular joint involvement, and higher JADAS-27 at bDMARD initiation were associated with D2T status (p < 0.05). D2T course was associated with temporomandibular joint involvement, elevated inflammatory markers, and higher disease activity at the initiation of the first biologic therapy.
Tocilizumab-induced psoriatic dermatitis in polyarticular juvenile idiopathic arthritis: A rare case report.
Psoriasis is an immune-mediated inflammatory disorder with a strong genetic predisposition. However, in some cases, it can emerge as an adverse effect of biologic therapy, particularly interleukin-6 inhibitors such as tocilizumab. This case report describes the unexpected onset of psoriatic dermatitis in a 16-year-old male diagnosed with polyarticular juvenile idiopathic arthritis following treatment with tocilizumab. The patient had no prior personal or family history of psoriasis, highlighting a potential paradoxical reaction to interleukin-6 inhibition. Management strategies included topical corticosteroids and vitamin D analogs, with consideration of dose adjustment or transition to an alternative biologic therapy. This case highlights the importance of recognizing dermatologic adverse effects associated with interleukin-6 inhibitors and emphasizes the need for individualized treatment strategies in juvenile idiopathic arthritis patients receiving biologic therapy.
Approval of Upadacitinib in Pediatric Patients with Active Polyarticular Juvenile Idiopathic Arthritis or Active Psoriatic Arthritis: A Regulatory Perspective.
On April 26, 2024, FDA approved Rinvoq (upadacitinib, extended-release [ER] tablets) and Rinvoq LQ (1 mg/mL oral solution), a new pediatric immediate-release (IR) formulation, for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) and active psoriatic arthritis (PsA) in patients 2 years of age and older. The approved dosing regimens include a weight-tiered twice daily (BID) regimen with IR oral solution and a once-daily (QD) regimen with ER tablets. The objective of this article is to summarize the FDA's major review findings and considerations supporting these approvals from a regulatory perspective. This clinical development program included a single study (Study 1) conducted in pediatric subjects aged 2 to less than 18 years with JIA with active polyarthritis to evaluate the pharmacokinetics (PK), safety, and tolerability of multiple doses of upadacitinib. No clinical trials or dedicated PK studies were conducted in pediatric patients with PsA. Efficacy was extrapolated from adults with rheumatoid arthritis (RA) or PsA to pediatric patients with pJIA or PsA, respectively, based on a PK-matching approach considering disease similarity, similar response to treatment, and comparable PK exposure. PK data analysis and simulations showed that the approved upadacitinib pediatric dosing regimen, including a BID regimen with IR oral solution and QD regimen with ER tablet, provide comparable PK exposure (Cmax and AUC) in pediatric subjects with pJIA or PsA as compared to the approved 15 mg ER tablet QD regimen in adults with RA or PsA, respectively, supporting the efficacy extrapolation from adults to pediatric subjects.
Real-life data on treatment strategies for polyarticular juvenile idiopathic arthritis.
Polyarticular juvenile idiopathic arthritis (pJIA) is one of the most difficult subgroups of JIA to manage. The aim of this study is to compare patients who were started on MTX at diagnosis and continued on monotherapy during follow-up with patients who later required the addition of bDMARDs. Patients with pJIA following up between January 2013 and December 2023 were included in the study. The juvenile arthritis disease activity score (JADAS) was used for disease activity, and the juvenile arthritis damage index (JADI) was used for damage status. The study included 78 pJIA patients, 56 (71.8%) of whom were girls. The median age at the time of pJIA diagnosis was 11.3 (IQR 6.6-14.3) years. The patients were divided into two groups: those receiving only methotrexate (MTX) (n = 23, 29.5%) and those receiving MTX and biologic disease-modifying anti-rheumatic drugs (bDMARDs) (n = 55, 70.5%). The time elapsed until diagnosis, elbow involvement, duration of follow-up, and time to achieve clinically inactive disease were all significantly higher in patients receiving MTX + bDMARDs (p < 0.05). No significant difference was observed in the JADAS-71 value at diagnosis (p > 0.05). The JADAS-71 and JADI values at the 3rd, 6th, and 12th months were also significantly higher in patients receiving MTX and bDMARDs (p < 0.05). Patients with pJIA can achieve remission with conventional DMARDs alone, such as methotrexate. Patients with high JADAS-71 and JADI-Articular (JADI-A) values may require the use of bDMARDs. In particular, high JADAS-71 values detected at the 6th month can be used as a predictor for starting bDMARDs in pJIA patients. • Polyarticular JIA is a challenging subtype with heterogeneous treatment responses. • Objective tools such as JADAS-71 are widely used to assess disease activity and support treatment monitoring. • JADAS-71 serves as a valuable tool to guide the timing of biologic therapy initiation in pJIA patients. • Although the management of pJIA is challenging for clinicians, some patients may achieve remission with only MTX.
Publicações recentes
[Clinical characteristics and outcomes analysis of children with rheumatoid factor-positive polyarticular juvenile idiopathic arthritis].
Status and progress in the development of rDNA-derived Tocilizumab and its biosimilars for treatment of rheumatoid arthritis.
A Case of Refractory Polyarticular Juvenile Idiopathic Arthritis Post-hematopoietic Stem Cell Transplantation Successfully Treated With Ruxolitinib.
Camptodactyly-Arthropathy-Coxa Vara-Pericarditis Syndrome without Camptodactyly: A Pediatric Case and Review of the Literature.
Biologic treatment patterns and challenges in defining difficult-to-treat disease in children with polyarticular juvenile idiopathic arthritis: a real-world study.
📚 EuropePMC159 artigos no totalmostrando 161
Camptodactyly-Arthropathy-Coxa Vara-Pericarditis Syndrome without Camptodactyly: A Pediatric Case and Review of the Literature.
Klinische PadiatrieBiologic treatment patterns and challenges in defining difficult-to-treat disease in children with polyarticular juvenile idiopathic arthritis: a real-world study.
Expert opinion on biological therapyOpen-Label Phase II Study of Olokizumab in Adolescent Patients with Polyarticular Juvenile Idiopathic Arthritis: Results of the 24-Week Treatment Period.
Pharmaceuticals (Basel, Switzerland)Tocilizumab-induced psoriatic dermatitis in polyarticular juvenile idiopathic arthritis: A rare case report.
SAGE open medical case reportsP19 A rare case of PHOAR2-enteropathy syndrome (PHOAR2E; previously known as pachydermoperiostosis) with a causal variant in the SLCO2A1 gene.
The British journal of dermatologyComparison of clinical practices during the transitional and young adult phases between patients with oligoarticular/polyarticular juvenile idiopathic arthritis and those with rheumatoid arthritis in Japan.
Pediatric rheumatology online journalEfficacy of biologic DMARDs in improving the clinical response of patients with polyarticular juvenile idiopathic arthritis: a meta-analysis of RCTs.
Advances in rheumatology (London, England)Real-life data on treatment strategies for polyarticular juvenile idiopathic arthritis.
European journal of pediatricsCT-P47/Tocilizumab-anoh: A Tocilizumab Biosimilar.
Clinical drug investigationApproval of Upadacitinib in Pediatric Patients with Active Polyarticular Juvenile Idiopathic Arthritis or Active Psoriatic Arthritis: A Regulatory Perspective.
Journal of clinical pharmacologyTelemedicine for paediatric rheumatic diseases in Japan: a national survey of physicians' perspectives.
Modern rheumatologyRare coexistence of X-linked hyper immunoglobulin M syndrome and polyarticular juvenile idiopathic arthritis in a Chinese child: A case report.
Joint diseases and related surgeryModel-Informed Paradigm in Drug Development-An End-To-End Case Study From Upadacitinib Development.
Clinical and translational scienceTreatment of polyarticular juvenile idiopathic arthritis in Latin America: recommendations from the Pan-American League of Associations for Rheumatology.
The Lancet. Child & adolescent healthInflammation-induced leg length discrepancy in children: from molecular mechanisms to clinical implications.
Frontiers in medicineThree-Year Outcomes and Latent Class Trajectory Analysis of the Childhood Arthritis and Rheumatology Research Alliance Polyarticular JIA Consensus Treatment Plans Study.
Arthritis & rheumatology (Hoboken, N.J.)Comparative efficacy and safety of etanercept and adalimumab in the treatment of polyarticular juvenile idiopathic arthritis.
BMC pediatricsClinical insights into heterogeneity of rheumatoid factor negative polyarticular juvenile idiopathic arthritis across the world.
Pediatric rheumatology online journalAfrican guidelines for diagnosis and management of polyarticular juvenile idiopathic arthritis: PAFLAR initiative.
Pediatric rheumatology online journalUsing genetics, genomics, and transcriptomics to identify therapeutic targets in juvenile idiopathic arthritis.
HGG advancesAn update on the safety of biologic therapies for the treatment of polyarticular juvenile idiopathic arthritis.
Expert opinion on drug safetyExperience with upadacitinib in refractory polyarticular juvenile idiopathic arthritis.
Rheumatology (Oxford, England)Characteristics of refractory disease and persistent symptoms in inflammatory arthritis: Qualitative framework analysis of interviews with patients and health care professionals.
British journal of health psychologyIdentification and validation of susceptibility modules and hub genes in polyarticular juvenile idiopathic arthritis using WGCNA and machine learning.
AutoimmunityPolyarticular juvenile idiopathic arthritis with Madelung deformity and arthritis mutilans in 18p deletion syndrome.
Rheumatology (Oxford, England)Intraarticular corticosteroid injections in pediatric rheumatology: insights from specialists.
European journal of pediatricsIncreased neutrophil extracellular trap formation in oligoarticular, polyarticular juvenile idiopathic arthritis and enthesitis-related arthritis: biomarkers for diagnosis and disease activity.
Frontiers in immunologyGenetic Mutations Associated With TNFAIP3 (A20) Haploinsufficiency and Their Impact on Inflammatory Diseases.
International journal of molecular sciencesFunctional status of Indian children with juvenile idiopathic arthritis.
Rheumatology and immunology researchUveitis as predictor of disease flare after the first anti-TNF withdrawal in oligoarticular and polyarticular juvenile idiopathic arthritis: a multicentric Italian experience.
Clinical and experimental rheumatologyTreatment Patterns in Polyarticular Juvenile Idiopathic Arthritis: A Retrospective Observational Health Claims Data Study.
Life (Basel, Switzerland)S100 proteins as potential predictive biomarkers of abatacept response in polyarticular juvenile idiopathic arthritis.
Arthritis research & therapyTranscriptomic signatures of classical monocytes reveal pro-inflammatory modules and heterogeneity in polyarticular juvenile idiopathic arthritis.
Frontiers in immunologyPolyarticular juvenile idiopathic arthritis with rice bodies formation: A case report.
International journal of rheumatic diseasesPolyarticular juvenile idiopathic arthritis has a distinct co-inhibitor receptor profile.
Rheumatology (Oxford, England)Loeffler's Endocarditis- A cause of endomyocardial fibrosis in a patient of juvenile idiopathic arthritis: A Case Report.
JPMA. The Journal of the Pakistan Medical AssociationTh17/1 and ex-Th17 cells are detected in patients with polyarticular juvenile arthritis and increase following treatment.
Pediatric rheumatology online journal[Protocols in pediatric rheumatology (PROKIND): treat-to-target in polyarticular juvenile idiopathic arthritis].
Zeitschrift fur RheumatologiePotential Process Control Issues With Abatacept.
Contact in contextRisk of flare in juvenile idiopathic arthritis: Is it related to the methotrexate treatment strategy or patient characteristics?
Archives of rheumatologyIdentification of key biomarkers in RF-negative polyarticular and oligoarticular juvenile idiopathic arthritis by bioinformatic analysis.
Pediatric rheumatology online journalInterleukin 6: at the interface of human health and disease.
Frontiers in immunologyChildren with extended oligoarticular and polyarticular juvenile idiopathic arthritis have alterations in B and T follicular cell subsets in peripheral blood and a cytokine profile sustaining B cell activation.
RMD openBone erosions associated with systemic bone loss on HR-pQCT in women with longstanding polyarticular juvenile idiopathic arthritis.
Seminars in arthritis and rheumatismRefractory inflammatory arthritis definition and model generated through patient and multi-disciplinary professional modified Delphi process.
PloS oneGolimumab for Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis: Pharmacologic and Clinical Considerations.
Life (Basel, Switzerland)Bradycardia after pulse methylprednisolone therapy in a child-Uncommon side effect of a frequently used drug: A case report.
Journal of family medicine and primary careBaricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
Lancet (London, England)Childhood-Onset COPA Syndrome Recognized Retrospectively in the Context of Polyarticular Juvenile Idiopathic Arthritis and Rheumatoid Arthritis.
Case reports in rheumatologyMicroscopic Polyangiitis with Pulmonary-renal Involvement in a Patient with Polyarticular Juvenile Idiopathic Arthritis: A Case Report.
Indian journal of nephrologyFactors associated with medication adherence among children with rheumatic diseases.
Frontiers in pharmacologyTherapeutic Development in Polyarticular Course Juvenile Idiopathic Arthritis: Extrapolation, Dose Selection, and Clinical Trial Design.
Arthritis & rheumatology (Hoboken, N.J.)Study of the shared gene signatures of polyarticular juvenile idiopathic arthritis and autoimmune uveitis.
Frontiers in immunologyPopulation Pharmacokinetics and Exposure-Response Modeling Analyses of Golimumab in Children and Young Adults With Recently Diagnosed Type 1 Diabetes.
Journal of clinical pharmacologyDry synovitis, a rare entity distinct from juvenile idiopathic arthritis.
Pediatric rheumatology online journalInvestigating Wrist Joint Position Sense and Hand Functions in Children With Polyarticular Juvenile Idiopathic Arthritis With Wrist Involvement.
Clinical pediatricsRisk stratification using anti-citrullinated peptide antibodies (ACPA) in polyarticular subtypes of juvenile idiopathic arthritis in adulthood.
Joint bone spineAqua-Plyometric Exercises-Induced Changes in Muscle Strength, Bone Mineral Properties, and Physical Fitness in Patients With Juvenile Idiopathic Arthritis: A 12-Week, Randomized Controlled Trial.
Pediatric exercise scienceEconomic evaluation of infliximab, synthetic triple therapy and methotrexate in the treatment of newly diagnosed juvenile idiopathic arthritis.
Pediatric rheumatology online journalBiologics with or without methotrexate in treatment of polyarticular juvenile idiopathic arthritis: effectiveness, safety and drug survival.
Rheumatology (Oxford, England)Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis and Subcutaneous Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Extrapolation of Data from Studies in Adults and Adjacent Pediatric Populations.
Paediatric drugsAtypical polyarticular juvenile idiopathic arthritis revealing multicentric reticulohistiocytosis with pulmonary involvement.
Rheumatology (Oxford, England)α2-fraction and haptoglobin as biomarkers for disease activity in oligo- and polyarticular juvenile idiopathic arthritis.
Pediatric rheumatology online journalOral or Parenteral Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis.
European journal of rheumatologyImpact of Clinical Pilates Exercise on Pain, Cardiorespiratory Fitness, Functional Ability, and Quality of Life in Children with Polyarticular Juvenile Idiopathic Arthritis.
International journal of environmental research and public healthThe Association Between the Use of Low-Slice Computed Tomography Machines and Downstream Care: Comparative Study of 16-Slice and 64-Slice Computed Tomography Angiography.
JMIR formative researchMitigated suppressive function of regulatory T cells (Treg) upon Th17-inducing cytokines in oligo- and polyarticular Juvenile Idiopathic Arthritis (JIA) patients.
Pediatric rheumatology online journalSocial determinants of health influence disease activity and functional disability in Polyarticular Juvenile Idiopathic Arthritis.
Pediatric rheumatology online journalEfficacy of tocilizumab for interstitial lung disease associated with polyarticular juvenile idiopathic arthritis.
Pediatrics international : official journal of the Japan Pediatric Society[Polyarticular juvenile idiopathic arthritis and rheumatoid arthritis : Common features and differences].
Zeitschrift fur RheumatologieLow-energy laser therapy application on knee joints as an auxiliary treatment in patients with polyarticular juvenile idiopathic arthritis: a dual-arm randomized clinical trial.
Lasers in medical scienceSubcutaneous golimumab induced and maintained clinical response in a child with a biological-experienced steroid-refractory flare of ulcerative colitis: A case report.
MedicineInterstitial lung disease occurring shortly after tocilizumab infusion in a patient with polyarticular juvenile idiopathic arthritis: a case report.
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical ImmunologyCommunity poverty level influences time to first pediatric rheumatology appointment in Polyarticular Juvenile Idiopathic Arthritis.
Pediatric rheumatology online journalA case report of intracranial hypertension and aseptic meningitis: anti-tumor necrosis factor associated or juvenile idiopathic arthritis related.
The Turkish journal of pediatricsJuvenile Idiopathic Arthritis-Associated Chronic Uveitis: Recent Therapeutic Approaches.
Journal of clinical medicineThe value of the patient global health assessment in polyarticular juvenile idiopathic arthritis: a nested cohort study.
Journal of patient-reported outcomesOptimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans.
Arthritis & rheumatology (Hoboken, N.J.)Improved Disease Course Associated With Early Initiation of Biologics in Polyarticular Juvenile Idiopathic Arthritis: Trajectory Analysis of a Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Study.
Arthritis & rheumatology (Hoboken, N.J.)Disseminated coccidioidomycosis in a patient with juvenile idiopathic arthritis receiving infliximab.
Pediatric rheumatology online journal[Cushing's syndrome with subsequent tertiary adrenocortical insufficiency after simultaneous multiple intra-articular local glucocorticoid treatment : Keep an eye on hormone deficiency conditions requiring treatment after multiple administrations of local steroids].
Zeitschrift fur RheumatologieRheumatoid factor positive polyarticular juvenile idiopathic arthritis associated with a novel COPA mutation.
Rheumatology (Oxford, England)Summarizing current refractory disease definitions in rheumatoid arthritis and polyarticular juvenile idiopathic arthritis: systematic review.
Rheumatology (Oxford, England)Underlying CTLA4 Deficiency in a Patient With Juvenile Idiopathic Arthritis and Autoimmune Lymphoproliferative Syndrome Features Successfully Treated With Abatacept-A Case Report.
Journal of pediatric hematology/oncologySubcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis.
Rheumatology (Oxford, England)Concentration of survivin in children with oligo- and polyarticular juvenile idiopathic arthritis (JIA): diagnostic and prognostic value-a single-center study.
Arthritis research & therapyOpen-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis.
Rheumatology (Oxford, England)Peripheral Blood Lymphocyte Analysis in Oligo- and Polyarticular Juvenile Idiopathic Arthritis Patients Receiving Methotrexate or Adalimumab Therapy: A Cross-Sectional Study.
Frontiers in pediatricsModel-Based Selection and Recommendation for Subcutaneous Abatacept Dose in Patients With Polyarticular Juvenile Idiopathic Arthritis.
Journal of clinical pharmacologyFallen, But Not Forgotten: Atlantoaxial Dislocation in a Child With Polyarticular Juvenile Idiopathic Arthritis in the Era of Biologics.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseasesLongitudinal assessment of racial disparities in juvenile idiopathic arthritis disease activity in a treat-to-target intervention.
Pediatric rheumatology online journalPlatelet Glycoprotein Ib α-Chain as a Putative Therapeutic Target for Juvenile Idiopathic Arthritis: A Mendelian Randomization Study.
Arthritis & rheumatology (Hoboken, N.J.)Coexistence of a novel WISP3 pathogenic variant and an MEFV mutation in an Arabic family with progressive pseudorheumatoid dysplasia mimicking polyarticular juvenile idiopathic arthritis.
Pediatric rheumatology online journalLong-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate.
RMD openImpact of core stability exercises on bone mineralization and functional capacity in children with polyarticular juvenile idiopathic arthritis: a randomized clinical trial.
Clinical rheumatologyType 1 interferonopathy presenting as juvenile idiopathic arthritis with interstitial lung disease: report of a new phenotype.
Pediatric rheumatology online journalTreat-to-target study for improved outcome in polyarticular juvenile idiopathic arthritis.
Annals of the rheumatic diseasesPADI4 (rs2240340), PDCD1 (rs10204525), and CTLA4 (231775) gene polymorphisms and polyarticular juvenile idiopathic arthritis.
British journal of biomedical sciencePediatric mesenteric panniculitis: three cases and a review of the literature.
The Turkish journal of pediatricsLow Incidence of Inflammatory Bowel Disease Adverse Events in Adalimumab Clinical Trials Across Nine Different Diseases.
Arthritis care & researchBiologic Therapies in Polyarticular Juvenile Idiopathic Arthritis. Comparison of Long-Term Safety Data from the German BIKER Registry.
ACR open rheumatologyArthritis in children with LRBA deficiency - case report and literature review.
Pediatric rheumatology online journalHealth-related quality of life during early aggressive treatment in patients with polyarticular juvenile idiopathic arthritis: results from randomized controlled trial.
Pediatric rheumatology online journalInfliximab therapy and outcomes in patients with polyarticular juvenile idiopathic arthritis: a single-center study in China.
World journal of pediatrics : WJPCanakinumab in Children with Familial Mediterranean Fever: A Single-Center, Retrospective Analysis.
Paediatric drugsEfficacy and safety of tocilizumab in a real-life observational cohort of patients with polyarticular juvenile idiopathic arthritis.
Rheumatology (Oxford, England)Outcome Monitoring and Clinical Decision Support in Polyarticular Juvenile Idiopathic Arthritis.
The Journal of rheumatologyExpanding the spectrum of A20 haploinsufficiency in two Chinese families: cases report.
BMC medical geneticsSlow speed resistance exercise training in children with polyarticular juvenile idiopathic arthritis.
Open access rheumatology : research and reviews[Biologics in the treatment of juvenile idiopathic arthritis : A comparison of mono- and combination therapy with synthetic DMARDs].
Zeitschrift fur RheumatologieBiallelic loss-of-function LACC1/FAMIN Mutations Presenting as Rheumatoid Factor-Negative Polyarticular Juvenile Idiopathic Arthritis.
Scientific reportsPopulation Pharmacokinetics and Exposure-Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative Colitis.
Journal of clinical pharmacologyPhysical Fitness in Patients With Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis Diagnosed in the Era of Biologics: A Controlled Cross-Sectional Study.
Arthritis care & researchHeight and sexual maturation in girls with juvenile idiopathic arthritis.
Jornal de pediatriaPhysical activity in patients with oligo- and polyarticular juvenile idiopathic arthritis diagnosed in the era of biologics: a controlled cross-sectional study.
Pediatric rheumatology online journalThe First Report of Multicentric Carpotarsal Osteolysis Syndrome Caused by MAFB Mutation in Asian.
Case reports in medicineSB5: An Adalimumab Biosimilar.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapyIdentification of enhanced IFN-γ signaling in polyarticular juvenile idiopathic arthritis with mass cytometry.
JCI insightSafety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease.
The Journal of pediatricsPAIN PERCEPTION AND PAIN COPING MECHANISMS IN CHILDREN AND ADOLESCENTS WITH JUVENILE FIBROMYALGIA AND POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS.
Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao PauloComparison of Adults With Polyarticular Juvenile Idiopathic Arthritis to Adults With Rheumatoid Arthritis: A Cross-sectional Analysis of Clinical Features and Medication Use.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseasesBilateral absence of the cruciate ligaments with meniscal dysplasia: Unexpected diagnosis in a child with juvenile idiopathic arthritis.
Clinical imagingIs palindromic rheumatism amongst children a benign disease?
Pediatric rheumatology online journalBrief Report: The Genetic Profile of Rheumatoid Factor-Positive Polyarticular Juvenile Idiopathic Arthritis Resembles That of Adult Rheumatoid Arthritis.
Arthritis & rheumatology (Hoboken, N.J.)Switched Memory B Cells Are Increased in Oligoarticular and Polyarticular Juvenile Idiopathic Arthritis and Their Change Over Time Is Related to Response to Tumor Necrosis Factor Inhibitors.
Arthritis & rheumatology (Hoboken, N.J.)Prior to extension, Transcriptomes of fibroblast-like Synoviocytes from extended and Polyarticular juvenile idiopathic arthritis are indistinguishable.
Pediatric rheumatology online journalEarly prediction for over two years efficacy of the first biologic agent for polyarticular juvenile idiopathic arthritis: A multi-institutional study in Japan.
Modern rheumatologyHigh Levels of DEK Autoantibodies in Sera of Patients With Polyarticular Juvenile Idiopathic Arthritis and With Early Disease Flares Following Cessation of Anti-Tumor Necrosis Factor Therapy.
Arthritis & rheumatology (Hoboken, N.J.)Adiposity in Juvenile Psoriatic Arthritis.
The Journal of rheumatologyPredictors of methotrexate response in Turkish children with oligoarticular and polyarticular juvenile idiopathic arthritis.
The Turkish journal of pediatricsProtocols on classification, monitoring and therapy in children's rheumatology (PRO-KIND): results of the working group Polyarticular juvenile idiopathic arthritis.
Pediatric rheumatology online journalSpontaneous regression of Epstein-Barr virus-associated lymphoproliferative disorder in a juvenile idiopathic arthritis patient after the discontinuation of methotrexate and etanercept.
European journal of rheumatologyGolimumab: A Review in Inflammatory Arthritis.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapyJuvenile Idiopathic Arthritis.
Balkan medical journalPlasma exchange successfully treated macrophage activation syndrome in rheumatoid factor-positive polyarticular juvenile idiopathic arthritis with co-existing pneumonia.
International journal of rheumatic diseasesSafety of tocilizumab in the treatment of juvenile idiopathic arthritis.
Expert opinion on drug safetyBiological agents in polyarticular juvenile idiopathic arthritis: A meta-analysis of randomized withdrawal trials.
Seminars in arthritis and rheumatismPathway analysis based on Monte Carlo Cross-Validation in polyarticular juvenile idiopathic arthritis.
Pathology, research and practiceComparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab.
Arthritis research & therapyA Novel Method for Pathway Identification Based on Attractor and Crosstalk in Polyarticular Juvenile Idiopathic Arthritis.
Medical science monitor : international medical journal of experimental and clinical researchInterleukin-33 as a marker of disease activity in rheumatoid factor positive polyarticular juvenile idiopathic arthritis.
Modern rheumatologyCost-Effectiveness Analysis of First-Line Treatment With Biologic Agents in Polyarticular Juvenile Idiopathic Arthritis.
Arthritis care & researchSafety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis.
Clinical rheumatologyMultifocal pigmented villonodular synovitis in a child: A case report.
MedicineNo association between vitamin D levels around time of birth and later risk of developing oligo- and polyarticular juvenile idiopathic arthritis: a Danish case-cohort study.
Scandinavian journal of rheumatologyProceedings of the 2016 Childhood Arthritis and Rheumatology Research Alliance (CARRA) Scientific Meeting : Toronto, Canada. 14-17 April 2016.
Pediatric rheumatology online journalWhole blood expression profiling from the TREAT trial: insights for the pathogenesis of polyarticular juvenile idiopathic arthritis.
Arthritis research & therapyMonitoring of Epstein-Barr virus load and killer T cells in patients with juvenile idiopathic arthritis treated with methotrexate or tocilizumab.
Modern rheumatologyPalisaded Neutrophilic Granulomatous Dermatitis in a Child with Juvenile Idiopathic Arthritis on Etanercept.
Pediatric dermatologyA novel reactive epitope-based antigen targeted by serum autoantibodies in oligoarticular and polyarticular juvenile idiopathic arthritis and development of an electrochemical biosensor.
ImmunobiologyAdalimumab in pediatric Crohn's disease.
ImmunotherapyJuvenile arthritis disease activity score is a better reflector of active disease than the disease activity score 28 in adults with polyarticular juvenile idiopathic arthritis.
Annals of the rheumatic diseasesPrediction of long-term remission of oligo/polyarticular juvenile idiopathic arthritis with S100A12 and vascular endothelial growth factor.
Modern rheumatologyDisease activity score in 28 joints at 3 months after the initiation of biologic agent can be a predictive target for switching to the second biologic agent in patients with polyarticular juvenile idiopathic arthritis.
Modern rheumatologyAdvances in the treatment of polyarticular juvenile idiopathic arthritis.
Current opinion in rheumatologyEffects of Combined Resistive Underwater Exercises and Interferential Current Therapy in Patients with Juvenile Idiopathic Arthritis: A Randomized Controlled Trial.
American journal of physical medicine & rehabilitationA new alternative therapy in dermatology: tocilizumab.
Cutaneous and ocular toxicologyAssociation between cannabinoid receptor type 2 Q63R variant and oligo/polyarticular juvenile idiopathic arthritis.
Scandinavian journal of rheumatologyLong-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).
Annals of the rheumatic diseasesRadiological improvement by tocilizumab in polyarticular juvenile idiopathic arthritis.
Pediatrics international : official journal of the Japan Pediatric SocietyX-linked agammaglobulinemia in two siblings with a novel mutation in the BTK gene who presented with polyarticular juvenile idiopathic arthritis.
Scandinavian journal of rheumatologyAssociações
Organizações que acompanham esta doença — pra ter apoio e orientação
Ainda não temos associações cadastradas para Poliartrite juvenil.
É de uma associação que acompanha esta doença? Fale com a gente →
Comunidades
Grupos ativos de quem convive com esta doença aqui no Raras
Ainda não existe comunidade no Raras para Poliartrite juvenil
Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.
Tire suas dúvidas
Perguntas, dicas e experiências compartilhadas aqui na página
Participe da discussão
Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.
Fazer loginDoenças relacionadas
Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico
Referências e fontes
Bases de dados externas citadas neste artigo
Publicações científicas
Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.
- Camptodactyly-Arthropathy-Coxa Vara-Pericarditis Syndrome without Camptodactyly: A Pediatric Case and Review of the Literature.
- Biologic treatment patterns and challenges in defining difficult-to-treat disease in children with polyarticular juvenile idiopathic arthritis: a real-world study.
- Tocilizumab-induced psoriatic dermatitis in polyarticular juvenile idiopathic arthritis: A rare case report.
- Approval of Upadacitinib in Pediatric Patients with Active Polyarticular Juvenile Idiopathic Arthritis or Active Psoriatic Arthritis: A Regulatory Perspective.
- Real-life data on treatment strategies for polyarticular juvenile idiopathic arthritis.
- [Clinical characteristics and outcomes analysis of children with rheumatoid factor-positive polyarticular juvenile idiopathic arthritis].
- Status and progress in the development of rDNA-derived Tocilizumab and its biosimilars for treatment of rheumatoid arthritis.
- A Case of Refractory Polyarticular Juvenile Idiopathic Arthritis Post-hematopoietic Stem Cell Transplantation Successfully Treated With Ruxolitinib.
Bases de dados e fontes oficiais
Identificadores e referências canônicas usadas para montar este verbete.
- ORPHA:404580(Orphanet)
- MONDO:0018456(MONDO)
- GARD:21729(GARD (NIH))
- Variantes catalogadas(ClinVar)
- Busca completa no PubMed(PubMed)
- Q56014153(Wikidata)
Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.
Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar
